| Document |
Document Title |
|
WO/2017/047816A1 |
The present invention provides a method for producing guanidine crosslinked artificial nucleic acid (abbreviated hereinafter as GuNA), and an intermediate compound for the production thereof. Specifically, the present invention provides ...
|
|
WO/2017/042038A1 |
The present disclosure relates to compositions and methods based on polypeptide-tagged nucleotide, and the use of such polypeptide-tagged nucleotides in nanopore devices and methods.
|
|
WO/2017/040896A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/040766A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/040895A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/040898A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/036356A1 |
Provided are a new crystal form of Fludarabine Phosphat, a preparation method therefor, a pharmaceutical composition containing same, and an application thereof in preparing medicine. Crystal forms I and II of the Fludarabine Phosphat ha...
|
|
WO/2017/040892A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/040899A2 |
|
|
WO/2017/040889A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/035453A1 |
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for treating solid tumors. In a specific embodiment, a method for treating a solid tumor in a patient...
|
|
WO/2017/031278A1 |
The present disclosure relates to processes for inverting oligonucleotide probes in an in situ synthesized array. These processes can be used to reverse the orientation of probes with respect to the substrate from 3 '-bound to 5 '-bound....
|
|
WO/2017/027980A1 |
There is provided a method for treating or preventing a Neisseria gonorrhoeae infection in a subject, comprising administering to the subject an effective amount of a compound of general formula I below or a pharmaceutical composition co...
|
|
WO/2017/029408A1 |
Disclosed are solid state forms of sofosbuvir. The solid state forms may be co-crystals of sofosbuvir with at least one co-crystal former.
|
|
WO/2017/031189A1 |
The invention provides compositions and methods for the production of TDP-deoxysugars.
|
|
WO/2017/023687A1 |
In one aspect, the present invention features a method of inhibiting proliferation and/or reducing survival of a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation, comprising contacting the cell with p...
|
|
WO/2017/024310A1 |
The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also pr...
|
|
WO/2017/023694A1 |
This invention relates the use of Cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neop...
|
|
WO/2017/019581A1 |
The present invention is directed to processes for making Compounds of Formula (IV): (IV) and salts thereof, wherein B, X, R1, R2, R3 and R4 are defined herein.
|
|
WO/2017/018360A1 |
Provided is an artificial nucleoside, or artificial nucleotide, that is a compound represented by formula (I) or a salt thereof. In formula (I), Bx is a pyrimidine base, thioxopyrimidine base, or purine base, R1, R2, R3 and R4 are hydrog...
|
|
WO/2017/019918A1 |
Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and thera...
|
|
WO/2017/009746A1 |
The present invention relates to an improved process for the preparation Sofosbuvir Formula (I). The present further relates to Sofosbuvir having a purity of greater than 99.5%.
|
|
WO/2017/001307A1 |
The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salts, enantiomers or diastereomers thereof, and compositions including the compounds for use in t...
|
|
WO/2017/004261A1 |
The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of crRNA. In cetain embodiments, such modified oligonucl...
|
|
WO/2017/004203A1 |
In certain embodiments, a method of detection includes providing cells labeled with a first element tag bound to a target RNA sequence and a second element tag bound to a target protein. The method may further include ionizing a cell, or...
|
|
WO/2017/004499A1 |
This invention relates to compositions and methods for the treatment of infection such as RSV, influenza, adenovirus, or rhinovirus.
|
|
WO/2016/210232A1 |
Topical compositions comprising niacinamide mononucleotide to improve the appearance of aging skin and to prevent and treat skin aging; and methods of use of topical compositions comprising niacinamide mononucleotide to improve the appea...
|
|
WO/2016/178876A9 |
The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection ...
|
|
WO/2016/200447A1 |
Compositions containing a combination of nicotinamide riboside and pterostilbene for treating skin disorders, and methods of treating skin disorders using these compositions and their equivalents are described. The skin disorders that ar...
|
|
WO/2016/201374A1 |
Described herein are sulfamide adenosine derivatives of Formula (I) or (II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods, uses, and kits involving the inventive compounds or p...
|
|
WO/2016/201025A1 |
Provided herein are photocrosslinking reagents, crosslinkable proteins displaying photocrosslinking groups, crosslinked protein-protein complexes, and methods of use thereof.
|
|
WO/2016/198948A1 |
Enzyme-based systems and methods for synthesizing the NAD precursors NMN and NaMN are disclosed. Such methods and systems utilize a mutated form of phosphoribosylpyrophosphate synthetase (PRS) that is superactive and/or other enzyme or e...
|
|
WO/2016/195353A1 |
The present invention provides to a cytidine deaminase (CDA)-resistant compound selected from the group consisting of 1'-cyano-cytarabine, 1'-cyano-gemcitabine, 1'-cyano-5-azacytidine and 1'-cyano-5-aza-2'-deoxycytidine, a prodrug or an ...
|
|
WO/2016/196735A2 |
The present disclosure provides new procedures and intermediates for the preparation of Sofosbuvir.
|
|
WO/2016/188943A1 |
The present invention relates to novel nucleoside derivatives of formula (I) as defined in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
|
|
WO/2016/188868A1 |
The invention relates to new nucleoside-lipid compounds with pH-sensitive dialkylorthoesterchains, to the process for their preparation and to their uses, in particular their use for transportation or vectorization of at least one therap...
|
|
WO/2016/189040A1 |
A process for preparing a nucleoside phosphoramidate, in particular to a process for preparing sofosbuvir, wherein a phosphoramidate derivative is used as starting material.
|
|
WO/2016/189287A1 |
The present disclosure relates to new compounds and their use as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications. The labels are advantageous due to their long S...
|
|
WO/2016/189055A1 |
The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
|
|
WO/2016/184361A1 |
Disclosed are a compound represented by general formula (I), and pharmaceutically acceptable salt thereof, wherein A is O or C=CH2; B is a nucleoside base; Z is a connecting bond or CHR4; when W is a connecting bond or C(O), R is CH(R')C...
|
|
WO/2016/182984A1 |
The present disclosure provides methods of sequencing polynucleotides and compounds, compositions useful for sequencing of polynucleotides. The chemical compounds include nucleotides and their analogs which possess a sugar moiety compris...
|
|
WO/2016/177300A1 |
Disclosed are a compound of formula I, and preparation method and intermediate thereof; the use of the compound of formula I in preparing a drug for treating viral infections; the use of the compound of formula I in preparing sofosbuvir ...
|
|
WO/2016/174081A1 |
The present invention relates to novel pro-drugs of L-2'-deoxythreose nucleoside phosphonates, such as phosphoramidate, phosphorodiamidate and phospho-diester prodrugs. The invention also relates to a process for preparing these novel pr...
|
|
WO/2016/176193A1 |
Disclosed herein is a method to specifically remove alloreactive T cells. In one example, the method includes culturing donor cells comprising donor T cells with recipient antigen presenting cells (APCs) to form a mixture of cells under ...
|
|
WO/2016/168911A1 |
The present invention is directed to purine nucleoside analogs of the general formula (I) or salts and pharmaceutical compositions comprising such compounds and salts, which are useful as anti-protozoan agents. The invention is also dire...
|
|
WO/2016/168735A1 |
In various embodiments, a cell culture medium, or a nucleoside cocktail transmission (NCT) medium for the culture of stem cells with improved genetic stability, cellular function and regeneration ability is provided. Illustrative culture...
|
|
WO/2016/168750A1 |
The present invention provides nucleic acid probes comprising two quenchers of excited state energy, and methods of their use.
|
|
WO/2016/160646A1 |
The present invention is directed to processs for making Compounds of Formula (II): (II), and salts thereof, wherein B, X, R2, R3, R4 R7, R8 and R9 are defined herein.
|
|
WO/2016/159836A1 |
The invention relates to the field of organic chemistry and medicine, and more particularly to synthetic substances of the pyrimidine series, namely 2-chloro-5-phenyl-5H-pyrimido[5',4':5,6]pyrano[2,3-d]pyrimid
ine-4-ol derivatives, havin...
|
|
WO/2016/160524A1 |
The invention provides a process for the preparation of nicotinamide mononucleotide having formula (I): The method involves the protection of nicotinamide riboside by ketalization, followed by phosphorylation and then deprotection to pro...
|
